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Objectives: To assess the level of research funding awarded to UK institutions specifically for antimicrobial
resistance-related research and how closely the topics funded relate to the clinical and public health burden of
resistance.
Methods: Databases and web sites were systematically searched for information on how infectious disease
research studies were funded for the period 1997–2010. Studies specifically related to antimicrobial resistance,
including bacteriology, virology, mycology and parasitology research, were identified and categorized in terms
of funding bypathogenanddiseaseandbya researchanddevelopment value chaindescribing the typeof science.
Results:Theoverall dataset included6165studies receivingatotal investmentof£2.6billion, ofwhich£102million
was directed towards antimicrobial resistance research (5.5% of total studies, 3.9% of total spend). Of 337 resist-
ance-related projects, 175 studies focused on bacteriology (40.2% of total resistance-related spending),
42 focused on antiviral resistance (17.2% of funding) and 51 focused on parasitology (27.4% of funding).
Mean annual funding ranged from £1.9 million in 1997 to £22.1 million in 2009.
Conclusions: Despite the fact that the emergence of antimicrobial resistance threatens our future ability to treat
many infections, theproportionof theUK infection-research spend targeting this important area is small. Thereare
encouraging signs of increased investment in this area, but it is important that this is sustained and targeted at
areas of projected greatest burden. Two areas of particular concern requiring more investment are tuberculosis
and multidrug-resistant Gram-negative bacteria.
Keywords: antibiotics, antifungal, antiviral, antiparasitic
Introduction
Infections caused by antimicrobial-resistant microorganisms are
oftenassociatedwithpoorclinical outcomes, resulting in increased
morbidity and mortality. Many factors contribute to the spread
of drug-resistant infections, including weak health systems,1,2
failing public health control,3 population movements and inter-
national travel of peoplewhomaybe infectedorasymptomatically
colonized by resistant strains,4 unregulated use of antibiotics
in many parts of the world5 and inappropriate drug use in count-
ries with tighter regulation.4,6 There are also biological factors,
including spread of resistant strains and spread of mobile genetic
elements, that can transfer resistance genes between strains,
species and genera. The resistance problems that we now face
are exacerbated even further by the dwindling developmental
pipeline for new antibiotics.7
The burden of resistance changes over time. Methicillin-resistant
Staphylococcusaureus (MRSA)bacteraemias in theUKwere reduced
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from7790 in 2003/04 to 1481 in 2010/11 andmacrolide resistance
in pneumococci causing bacteraemias declined from 11%–14%
in 2005 to 5% by 2009.8 However, also in the UK, there was
,2% imipenem resistance in Acinetobacter spp. in 2000, rising to
30%by2008, andwhile therewereno reportsof cefixime resistance
in Neisseria gonorrhoeae in 2005, rates of 12% were reported in
2009.8 Outside of the UK, in 1997–98, extended-spectrum
b-lactamases (ESBLs) were present in 13%–35% of Escherichia
coli from Chinese centres participating in the SENTRY surveillance,9
which had increased to 50%–80% by 2007,10 and the number of
cases of multidrug-resistant tuberculosis reported by 27 countries
with a high burden of disease almost doubled between 2009 and
2011.11
Antimicrobial resistance therefore presentsmanyopportunities
andneeds for research, ranging from (i) the discoveryanddevelop-
ment of new agents, through (ii) basic, applied and public health-
focused researchon resistancemechanismsand theepidemiology
of resistant organisms and their resistance elements, to (iii)
improved diagnostics for early detection of resistance and clinical
trials of different treatment options or influencing usageof antimi-
crobials, to (iv) social sciences/behavioural/health services/policy
research and (v) economic research.
UK research institutions received at least £2.6 billion of public
and philanthropic funding to carry out infectious disease research
between1997and2010 fromavarietyofnationaland internation-
al funding sources.12 These included the Wellcome Trust, Medical
ResearchCouncil, Department ofHealth, Bill &MelindaGates Foun-
dation, European Commission and a range of other bodies, depart-
mentsand researchcharities. This fundingwasspentonall typesof
science along the research pipeline, from laboratory studies to op-
erational research and translational medicine. We report here the
research funding that was awarded to UK institutions specifically
for antimicrobial resistance-related research, along with temporal
trends and the relative proportions allocated. We assess how
closely the topics funded relate to the clinical and public health
burden of resistance, seeking to identify potential funding gaps
that policy makers and funders can be encouraged to focus on in
future, and areas where the UK has clear research strengths.
Methods
The analyses in this paper focused on studies funded in a 14 year period
(1997–2010 inclusive) that were relevant to, or had specific mention of,
antimicrobial resistance in any of bacteriology, virology, mycology and
parasitology research. Antimicrobial resistance studies were defined as
those thatmade specific reference to resistance to one ormore antimicro-
bials or focused on an area ofmicrobiology of clear relevance to resistance
(e.g. MRSA). Global health studies were defined as those that investigated
diseases not endemic in the UK (such as malaria or schistosomiasis) or
where the study had a clear reference to another country (e.g. tuberculosis
in South Africa). No private sector funding was included in this analysis, as
the publicly available data are very limited from these sources and were
considered to be under-representative.
The methods have been described in detail elsewhere,12 but are reiter-
ated briefly here. The overarching dataset was obtained from several
sources of public and charitable funding for infectious disease research
studies, including the Wellcome Trust, the Medical Research Council and
other research councils, UK government departments, the European Com-
mission and the Bill & Melinda Gates Foundation and other research char-
ities. Data collection was via: (i) downloading all data from the funder
web site andmanually filtering the infectious disease studies; (ii) searching
openaccessdatabasesonthe funderwebsite for infection-relatedkeyword
terms; or (iii) contacting the funder directly and requesting details of their
infection studies. Funders were identified through the authors’ knowledge
of the research and development (R&D) landscape and searches of the
Internet. The majority of data extraction was performed by author
M. G. H., with support from authors J. R. F., F. B. W. and M. K. C. Each study
was assigned to as many primary disease categories as appropriate.13
Within each category, topic-specific subsections (including specific patho-
gen or disease) were documented. Studies were also allocated to one of
four R&D categories: pre-clinical; Phase 1, 2 or 3; product development;
and implementation and operational research (including surveillance, epi-
demiologyand statistical andmodelling projects). Funderswere eithercon-
sidered in their own right or, for convenience, some were grouped into
categories, such as in-houseuniversity funding, research charities andgov-
ernment departments. A total of 26 funder categorieswere used.13 Studies
wereexcluded if: (i) theywerenot immediately relevant to infection; (ii) they
were veterinary infectious disease research studies; (iii) they concerned the
use of viral vectors to investigate non-communicable diseases; (iv) they
were grants for symposia or meetings; or (v) they included UK researchers,
but with the funding awarded to and administered through a non-UK insti-
tution. Studies that made reference to related areas such as antimicrobial
stewardship or development of new therapeutics were excluded unless
there was specific mention of resistance in the title or abstract. Unfunded
studies were also excluded. Grants awarded in a currency other than
pounds sterling were converted into UK pounds using the mean exchange
rate in the year of the award. All awards were adjusted for inflation and
reported in 2010 UK pounds. Analysis was carried out in Microsoftw Excel
and Access (versions 2000 and 2007) and Stata (version 11).
Results
We identified 6165 studies funded within the 14 year period and
covering all infectious disease research representing a total invest-
ment of £2.6 billion (Table 1). Despite the global impact and clinical
importance of antimicrobial resistance, by funding volume this re-
search area ranked only 14th out of the 38 primary disease cat-
egories.13 Three hundred and thirty-seven studies were funded
for antimicrobial resistance research, comprising 5.5% of total in-
fectious disease research projects. These were awarded £102.0
million; only 3.9% of the total spend, with a median award of
£120000 (Table 1). If tuberculosis, HIV and malaria are not
included, then the total antimicrobial research spend is £62.5
million (Figure 1).
Of the 337 resistance-related projects, 51.9% (n¼175) focused
on bacteriology (Table 1), but these attracted only 40.2% (£41.0
million) of total resistance-related spending, with a median award
of £112000. Studies on antiviral resistance (n¼42) represented
12.5% of resistance-related projects and were awarded 17.2%
of the resistance-related funding (median award £121000).
In contrast, parasitology studies (n¼51) represented 15.1% of
resistance-related projects, but were awarded 27.4% of funding
withamedianawardof£223000.Hence, a substantial proportion
of the funding awarded to UK institutions for resistance-related
research over the 14 year study period was for projects addressing
global health issues. In particular, studies on resistance in malaria
were awarded £21.3 million across 35 studies (Table 2). Thirty-four
percent (£34.8 million) of the total funding for antimicrobial resist-
ance was related to global health.
Pre-clinical research received £58.0 million across 191 studies,
Phase 1–3 studies received £1.2 million across 3 studies, product
development research received £4.2 million across 20 studies
Funding antimicrobial resistance research
549
JAC
and implementation and operational research received £38.6
million across 123 studies.
Studies related to resistance in staphylococci received £15.9
million across 76 studies, of which 28 were pre-clinical and 41
were implementation and operational research. Twelve studies,
totalling £9.1million, looked specificallyat resistanceand tubercu-
losis and were a mixture of implementation research (7 studies)
and pre-clinical science (5 studies). Two of the implementation
studies were related to work in Africa and two to Asia. There were
just two studies specifically on E. coli resistance and one more
looking at ESBLs generally. There were 30 HIV studies receiving
£20.7 million, of which 16 were pre-clinical and 10 were imple-
mentation and operational research. Modelling and economics
research was limited to nine studies (total funding £1.1 million,
median funding £130219).
There were no clear temporal trends in the levels of overall
funding (although it appears that funding may be increasing
overall) or in awards made by particular funding bodies (Figure 2).
The mean funding for resistance-related research was £7.2 million
per annum, but ranged from £1.9 million in 1997 to £22.1 million
in 2009. The mean funding awarded per study was £302731
(SD £752544), with median funding per study considerably lower
at £119685 (IQR £31889–254591), demonstrating the skewed
distribution of the awards (there were 146 awards of less than
£100000 and 9 awards of more than £1million).
Discussion
This study is the first systematic analysis of research funding for
antimicrobial resistance. Over the 14 year study period analysed,
337 studieswere identified that related to antimicrobial resistance
where public and philanthropic funding had been awarded to a UK
institution. Themajority of projects (51.9%; £41.0million) focused
on bacteriology. There was also a focus on pre-clinical science
(57%; £58.0 million). Nevertheless, bacteriology-focused resist-
anceprojects didnot attract pro rata levels of funding, accounting
for 52% of funded projects, but only 40% of the total spend;
virology- and, especially, parasitology-focused resistance pro-
jects attracted larger awards. Two hundred and nine studies
investigated resistance, usually in bacteria, but did not specify a
pathogen.
The ChiefMedical Officer (CMO) for Englandmade antimicrobial
resistance, especially in bacteria, a priority area in her annual
report, published in 2013,14,15 and the Department of Health
later issued an e-mail bulletin highlighting a call for research in
this area, to be released in the autumn of 2013 across the major
funding streams of the National Institute for Health Research.16
Thus there has been a clear acknowledgement within the UK
political arena that there are significant challenges in this area
that need to be met. The scientific community has repeatedly
highlighted the threats posed by the emergence and spread of
antibacterial resistance nationally and globally,17 and the lack of
new antimicrobials being developed,18–20 but this study suggests
that the research portfolio in this area of antimicrobial resistance
appears to be relatively small.
There are now large international collaborative schemes, such
as theNational Institutes of Health Public–Private Partnership pro-
gramme and the Innovative Medicines Initiative (IMI) supported
jointly by the European Union and the European Federation of
Pharmaceutical Industries and Associations.21 Part of the IMI
has a mission to identify novel lead molecules for antibiotic
Table 1. Funding awarded to UK institutions for research on infectious disease ranked by numbers of awards for antimicrobial resistance-related
projects
Microbiological
subject area
Total research funding awarded Antimicrobial resistance-related funding
number of
studies (%)
total investment,
£ millions (%)
median grant
award, £
number of
studies (%)
total investment,
£ millions (%)
median
grant
award, £
Bacteriology 1995 (32.8) 588.3 (22.6) 162281 175 (51.9) 41.0 (40.2) 112152
Parasitology 1067 (17.6) 666.9 (25.7) 216260 51 (15.1) 27.9 (27.4) 222912
Virology 2147 (35.4) 1027.4 (39.5) 160555 42 (12.5) 17.5 (17.2) 120926
Mycology 171 (2.8) 48.4 (1.9) 138258 14 (4.2) 1.5 (1.5) 91761
Prion 48 (0.8) 33.5 (1.3) 381587 — — —
Not specified 914 (15.1) 329 (12.7) 126179 55 (16.3) 14.5 (14.2) 115120
Overall 6165 (100) 2600.0 (100) 158055 337 (5.5) 102.0 (3.9) 119685
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Figure1. Sumof fundingawardedforantimicrobial research (AMR) studies,
1997–2010, with and without inclusion of the ‘big three’ of tuberculosis
(TB), malaria and HIV.
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Table 2. Breakdown of investments directed to specific infection
Topic area Specific infection
Total research funding awarded Antimicrobial resistance-related funding
number of
studies (%)
total investment,
£ millions (%)
median grant
award, £
number of
studies (%)
total investment,
£ millions (%)
median grant
award, £
Bacteriology Campylobacter 87 (1.4) 24.1 (0.9) 221532 0 0 0
chlamydia 112 (1.8) 21.7 (0.8) 50469 1 (0.3) 0.2 (0.8) 165260
Clostridium 78 (1.3) 35.4 (1.4) 204389 2 (0.6) 0.6 (2.1) 315676
diphtheria 2 (0) 0.1 (0) 69931 0 0 0
E. coli 107 (1.7) 26.3 (1.0) 206784 2 (0.6) 0.2 (0.7) 89448
gonorrhoea 18 (0.3) 0.9 (0) 7548 1 (0.3) 0.01 (0.8) 7441
Helicobacter 101 (1.6) 15.1 (0.6) 83986 2 (0.6) 0.02 (0.1) 8310
leprosy 2 (0.0) 0.6 (0.0) 311540 0 0 0
Listeria 11 (0.2) 4.9 (0.2) 239595 0 0 0
meningitis 222 (3.6) 54.0 (2.1) 146153 6 (1.8) 1.1 (2.0) 137022
pertussis 9 (0.1) 2.4 (0.1) 299840 0 0 0
Pseudomonas 43 (0.7) 6.5 (0.2) 81793 3 (0.9) 0.5 (7.8) 243667
Salmonella 145 (2.4) 55.7 (2.1) 256185 7 (2.1) 3.0 (5.4) 384998
Shigella 9 (0.1) 3.3 (0.1) 211456 0 0 0
Staphylococcus 139 (2.3) 31.6 (1.2) 114502 76 (22.6) 15.9 (50.2) 81927
Streptococcus 70 (1.1) 16.7 (0.6) 161869 5 (1.5) 0.6 (3.4) 101876
syphilis 5 (0.1) 1.1 (0.0) 207346 0 0 0
tetanus 5 (0.1) 5.1 (0.2) 0 0 0
trachoma 2 (0.0) 3.7 (0.1) 1859286 0 0 0
tuberculosis 329 (5.3) 155.3 (6.0) 190467 12 (3.7) 9.1 (6.1) 260866
Parasitology African
trypanosomiasis
76 (1.2) 42.8 (1.6) 262145 4 (1.2) 1.9 (4.0) 323869
Chagas disease 18 (0.2) 4.9 (0.2) 215639 0 0 0
helminths 150 (2.4) 67.9 (2.6) 233772 5 (4.4) 1.3 (2.8) 248586
leishmaniasis 78 (1.3) 41.8 (1.6) 289354 4 (5.3) 2.9 (8.1) 452751
lymphatic filariasis 7 (0.1) 47.0 (1.8) 551459 0 0 0
malaria 504 (8.1) 352.9 (13.6) 203348 35 (7.0) 21.3 (6.2) 219834
onchocerciasis 5 (0.1) 1.7 (0.1) 35769 0 0 0
schistosomiasis 47 (0.7) 40.8 (1.6) 197557 0 0 0
Virology CMV 68 (1.1) 28.4 (1.1) 188607 2 (2.9) 0.2 (0.6) 90093
dengue 29 (0.5) 43.8 (1.7) 269824 1 (3.6) 0.1 (0.2) 95888
EBV 146 (2.4) 44.6 (1.7) 156697 2 (1.4) 1.1 (2.4) 548026
hepatitis B 68 (1.1) 11.8 (0.5) 65624 3 (4.4) 0.1 (0.9) 11794
hepatitis C 235 (3.8) 59.7 (2.3) 116883 1 (0.4) 0.1 (0.1) 64706
HIV 764 (12.4) 477.6 (18.4) 147404 30 (3.9) 20.7 (4.5) 155583
HPV 147 (2.4) 52.2 (2.0) 92143 0 0 0
HSV 48 (0.8) 22.1 (0.8) 202564 0 0 0
influenza 141 (2.3) 80.0 (3.1) 299988 2 (1.4) 0.6 (0.8) 303676
measles 12 (0.2) 5.0 (0.2) 284882 0 0 0
norovirus 12 (0.2) 5.1 (0.2) 200621 0 0 0
polio 4 (0.1) 1.2 (0.0) 164849 0 0 0
rotavirus 19 (0.3) 6.1 (0.2) 164690 0 0 0
RSV 45 (0.7) 16.9 (0.6) 184292 0 0 0
VZV 20 (0.3) 4.2 (0.2) 145505 0 0 0
Mycology Aspergillus 26 (0.4) 4.9 (0.2) 47948 1 (3.8) 0.1 (2.3) 112397
Candida 71 (1.2) 19.1 (0.8) 253498 6 (8.5) 0.8 (4.2) 98641
Other or pathogen
not specified
2572 (41.7) 935.7 (36.0) 153330 220 (8.6) 50.4 (5.4) 101258
Overall 6165 2600.0 158055 337 (5.5) 102.0 (3.9) 119685
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development and this collaboration could be particularly import-
ant, in termsofhighlighting thebestdirection forefficientantibiotic
development R&D programmes and appropriate models of how
the private and public sectors can best work together.
The time period analysed for this study broadly coincides with
what has been described as the ‘rise and fall’ of one of the UK’s
highest-profile resistance problems, that of MRSA.8 From a peak
in 2003, there has been a general decline in the rate of MRSA bac-
teraemia in England since 2006.22 Just 19 MRSA research studies
were funded from 1997 to 2002, increasing to 57 from 2003 to
2010. Given thatmuch of this was translational work and hospital
focused, it is possible that research hasmade a timely contribution
to the declines in recorded bacteraemias. However, despite
success with reducing MRSA, new problems have gained promin-
ence. Resistance rates in many Gram-negative bacteria have
increased throughout the period analysed.23,24 They represent a
growing public health threat and indicate the most pressing need
for new antibiotics. These bacteria now also have a raised political
profile, with the CMO for England highlighting concerns over
multidrug-resistant strains of N. gonorrhoeae and strains of Enter-
obacteriaceae, particularly E. coli and Klebsiella pneumoniae, in
both community and healthcare settingswith ESBLs and carbape-
nemases.14,15 Awards to UK institutions to undertake research in
this particular area appeared to be minimal, though some of the
studies may have had a tangential focus here and the analysis
may have excluded antimicrobial resistance studies involving UK
collaborators but led elsewhere. Also, awards were analysed only
up to and including 2010. Subsequent to this period, a report by
the Joint Working Group of DARC (Defra Antimicrobial Resistance
Coordination) and ARHAI (Advisory Committee on Antimicrobial
Resistance and Healthcare Associated Infections), entitled ESBLs:
AThreat toHumanandAnimal Health?,25was followedbya specific
funding call by theDepartment of Health in England to address the
research and evidence gap surrounding this particular resist-
ance.26 The spread of carbapenemases, however, remains a
topic for greater focus by funders and researchers.
The worldwide burden of drug-resistant tuberculosis is increas-
ing, with WHO estimates of 630000 cases of multidrug-resistant
tuberculosis worldwide, great variation between countries and
emergence over the last decade of extensively drug-resistant
cases.27 With the highlighted difficulties in the development of an
improved vaccine,28 research into effective tuberculosis treatments
becomes even more important. The UK arguably should sustain
greater activity in this R&D, with a focus both in the UK and
internationally, directing research resources to areas of current
and projected future high burden of tuberculosis resistance.
Within parasitology-related resistance research, themain focus
(both funding and study numbers) was on malaria with the rest
being distributed relatively thinly amongst leishmaniasis, trypano-
somiasis and helminth infections. Resistance of the malaria para-
site Plasmodium falciparum to antiparasitic drugs is well known,
with theWHO launching the Global Plan for Artemisinin Resistance
Containment.29 Themalaria out put of this datasetwas predomin-
antlybasic science,with fewer studies focusingon implementation
and operational research. Malaria research generally has been a
strength of UK institutions12 and the number of studies investigat-
ing this areaof resistance is encouraging.Within neglected tropical
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Figure 2. Sum of funding awarded for antimicrobial research studies,
1997–2010, according to (a) top funders, (b) type of funding and (c)
stage of research pipeline.
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diseases (NTDs, as defined by WHO30), the work is almost entirely
pre-clinical apart from one study on implementation research
and another on product development. Although NTDs are well
funded generally, relative to the overall dataset,12 the fewprojects
on resistance may actually reflect a poorer knowledge base (than
malaria). If so, then strengthening surveillance systems in coun-
tries of endemic infection toquickly identifyanyemerging patterns
of resistance and using the surveillance data for research could be
an interesting area to prioritize.
Of the 30 studies related to HIV, just three studies—each
awarded more than £1 million and with two focused on interven-
tions in Africa—were collectively awarded .50% of the total HIV
funding. The median award for HIV research was substantially
less than the malaria resistance portfolio (£155583 versus
£219834)andtherewasabalancebetweenpre-clinicaland imple-
mentation research, perhaps illustrating the more advanced pool
of knowledge within HIV compared with, for example, NTDs.
The study has several limitations, which have been highlighted
and discussed in detail elsewhere.12 One particularly important
caveat arises from the difficulty in obtaining details, and hence the
exclusion here, of private sector research funding. For the true
picture to emerge, private sector data must be analysed to the
same level of detail achieved here for data obtained from public
sector and charitable foundations. The success of the Policy Cures
initiative31 toobtain industrydata isencouragingfor futureanalyses.
Another limitationarises because it is difficult toassessassociations
with other areas of research that are not directly related to resist-
ance,butwhichnonethelesshavean impact, e.g.preventativemea-
sures such as vaccine development and enhancing treatment
adherence. Also, it was not feasible to assess how much funding
was distributed from the lead institution to their collaborative part-
ners, nor was it possible to quantify what proportion of a grant
should be allocated to each of the allocated disease categories.
With an increasing globalization in both the transmission of in-
fectious diseases and also the opportunities for institutions to col-
laborateacross borders, there is an increasingneed for global data.
The Global Burden of Disease Study32 illustrates the usefulness of
such collaborations and Policy Cures shows how an international
approach to obtaining neglected disease funding can be applied.
There is a need for funders fromother countries to provide similarly
detailed information of funded studies, in order to build a global
database of projects. This would be of great help in identifying
true research gaps, reducing unnecessary duplication of research,
pinpointing where there is infrastructure and capacity for specific
types of research requiring technologyor skills, andaiding in asses-
sing global priorities.
To conclude, political leadership, sustained funding and the
implementation of global and regional action plans have been
highlighted as important facets of any attempt to reduce and
combat antimicrobial resistance.27 The stimulation of new part-
nerships between the public and private sectors may give new
stimulus to the development of new antimicrobials, but there
appears to be broad neglect of resistance generally from public
and philanthropic funding in the UK, when compared with
funding awarded to other infectious disease-related topics. There-
fore, there must be consideration of increased funding for
research into areas such as epidemiology, modelling, economics,
policy and behavioural research, intervention studies aimed at re-
ducing resistance and further pre-clinical research using new tech-
nologies such as whole genome sequencing.33 Tuberculosis and
multidrug-resistant Gram-negative bacteria are arguably the two
areas of potentially greatest future burden. The UK shows a good
example in carrying out research across all areas of infection
that is categorized as global health and thus of primary benefit
to other countries, and this should continue to be reflected in
resistance-related R&D. However, the somewhat reactive nature
of the response to the problem indicates that lessons should be
learned in setting aside future funding for emerging issues within
infectious diseases generally and specifically here within anti-
microbial resistance. Researchers should be encouraged to
develop high-quality bids and funders encouraged to consider
their possible impact in reducing future disease and economic
burdens. Funders based in other countries should also be encour-
aged to release their funding data for similar systematic analyses,
to allow the construction of a global database of previous and
current antimicrobial resistance projects.
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